| Metric | Value (₹ Cr) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 6.0K | 85.2% | 76.1% |
| Total Income | 6.2K | 89.8% | 79.9% |
| Expenditure | 3.9K | 35.6% | 29.8% |
| PBT | 967.40 | 912.2% | 104.7% |
| Net Profit | 610.43 | 1199.5% | 72.2% |
| OPM | 16.11% | 8.23pp | 8.41pp |
| NPM | 9.77% | 8.34pp | 0.44pp |
| EPS | 21.63 | 1203.0% | 72.3% |
Glenmark Pharmaceuticals Announces Q2FY26 Results: Revenue Up by 76.1% YoY, EBITDA Margin at 39%, PAT Margin at 10.1%
14 Nov 2025 · 14 Nov 2025, 06:14 pm
Summary
Glenmark Pharmaceuticals Ltd. has announced its financial results for the second quarter ended September 30, 2025. The company's consolidated revenue was at Rs. 60,469 Mn, up 76.1% YoY. EBITDA was Rs. 23,596 Mn with an EBITDA margin of 39%. Profit After Tax (PAT) was Rs. 6,104 Mn with a PAT margin of 10.1%.
Key Highlights
- 1
Europe revenue up by 8.5% YoY to Rs. 7,460 Mn
- 2
North America business grew by 7.4% (Net of the out-licensing income of the ISB 2001 deal)
- 3
India Formulations revenue at Rs. 1,650 Mn
- 4
Emerging Markets revenue at Rs. 6,585 Mn
- 5
EBITDA of Rs. 23,596 Mn, up 292% YoY, with an EBITDA margin of 39%
- 6
Profit After Tax (PAT) of Rs. 6,104 Mn, up 72.2% YoY with PAT margin of 10.1%
Management Comments
Glenn Saldanha
Chairman & Managing Director, Glenmark Pharmaceuticals Ltd.
Q2FY26 reflects the steady progress we are making in strengthening Glenmark’s scientific and strategic foundation. The AbbVie partnership for ISB 2001, along with the income recognised this quarter, is a significant validation of our scientific strength and enables us to advance the pipeline in a financially self-sustaining way. Across key markets, our performance remained resilient. North America delivered a continued uptick in performance, supported by the expansion of our injectable portfolio and steady execution across institutional channels. Europe returned to its growth trajectory, backed by recent product launches. In India, GST-related adjustments, given our unique three-tiered distribution model, had a one-time impact on primary sales; however secondary sales continue to outperform IPM, and we expect reported growth to normalize from Q3 onwards. Our specialty and innovation businesses progressed several important milestones this quarter including the global expansion of RYALTRIS®, the UK launch of WINLEVI®, the regulatory and clinical milestones achieved for QiNHAYO™, and our IGI oncology assets. We remain committed to disciplined execution, advancing meaningful science, and delivering sustained value for our patients, partners, and all stakeholders.
Informational and educational content only. Not investment advice.